Randomized phase 3 study of first-line selpercatinib versus chemotherapy and pembrolizumab in RET fusion-positive NSCLC Meeting Abstract
| Authors: | Loong, H.; Goto, K.; Solomon, B.; Park, K.; PeĢrol, M.; Arriola, E.; Novello, S.; Cheng, Y.; Ardizzoni, A.; Mak, M.; Santini, F.; Elamin, Y.; Drilon, A.; Wolf, J.; Han, B.; Han, H.; Uh, M.; Puri, T.; Soldatenkova, V.; Zhou, C. |
| Abstract Title: | Randomized phase 3 study of first-line selpercatinib versus chemotherapy and pembrolizumab in RET fusion-positive NSCLC |
| Meeting Title: | 36. Deutscher Krebskongress - Fortschritt gemeinsam gestalten |
| Journal Title: | Oncology Research and Treatment |
| Volume: | 47 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2024 Feb 21-24 |
| Meeting Location: | Berlin, Germany |
| ISSN: | 2296-5270 |
| Publisher: | S. Karger AG |
| Date Published: | 2024-02-01 |
| Start Page: | 246 |
| Language: | English |
| ACCESSION: | WOS:001332646400607 |
| PROVIDER: | wos |
| DOI: | 10.1159/000535363 |
| Notes: | Meeting Abstract: 1108 -- 'The 36th German Cancer Congress - Building Progress Together' -- Located in the section 'Lung Cancer' (Late Breaking) -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
